Sholpan Primbetova

Ms. Sholpan Primbetova

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in Drug and Alcohol Dependence
Verified
Journal Article
Open access
TTTerlikbayeva Terlikbayeva
Terlikbayeva Terlikbayeva
BZBaurzhan Zhussupov
Baurzhan Zhussupov
Sholpan PrimbetovaSholpan Primbetova
Sholpan Primbetova
LGLouisa Gilbert
Louisa Gilbert
NANurmat Atabekov
Nurmat Atabekov
NENabila El-Bassel
Nabila El-Bassel
As a population profoundly affected by the HIV epidemic and in critical need of linkages to HIV treatment and care, PWID in Central Asia remain largely underserved. This paper provides an overview of the current state of HIV testing and counseling in Central Asia for PWID, identifies main barriers leading to gaps in service delivery, and discusses implications for improving strategies that promote HIV testing for PWID. We reviewed a number of sources for this paper including unpublished government reports, published papers, and Ministries of Health of Kazakhstan, Kyrgyzstan, Tajikistan, and Uzbekistan country progress reports to the UN General Assembly Special Session on HIV/AIDS (UNGASS) for 2012. Between 29 and 65% of PLWH in some Central Asian countries have been tested for HIV in the last 12 months. The rates have been increasing in the recent years but still are relatively low. Stigma, discrimination, human rights violations, and repressive legislation are barriers to HTC for people who inject drugs (PWID). The use of innovative evidence-based HTC models, such as community mobile-vans, self-testing at home, and rapid HIV testing among PWID in Central Asia are discussed and recommendations given regarding amendments in legislation and scaling up of existing community-based pilot projects to support HIV testing among PWID in CA.

20 March 2018 in Trials
Verified
Journal Article
Open access
PDF file
TMTara McCrimmon
Tara McCrimmon
SWSusan Witte
Susan Witte
GMGaukhar Mergenova
Gaukhar Mergenova
TTTerlikbayeva Terlikbayeva
Terlikbayeva Terlikbayeva
Sholpan PrimbetovaSholpan Primbetova
Sholpan Primbetova
NENabila El-Bassel
Nabila El-Bassel
Among women at high risk for HIV and other sexually transmitted diseases (STIs), gender and economic issues limit the impact of behavioral prevention strategies. Women in Kazakhstan with dual risks of sex trading and drug use face elevated risk for HIV and STIs and may benefit from an economic empowerment intervention which combines HIV-risk reduction (HIVRR) education with financial skills-building and asset-building to promote reduced reliance on sex trading for income. The study employs a two-arm, cluster-randomized controlled trial (c-RCT) design. We will use cluster randomization to assign 350 women in approximately 50 cohorts to a traditional four-session HIV-risk-reduction intervention combined with a six-session financial literacy intervention, enrollment in a 24-session vocational training program and receipt of matched savings (HIVRR+MF); or to the four-session HIV-risk-reduction intervention alone (HIVRR). Repeated behavioral and biological assessments will be conducted at baseline, then at 6, 9, and 15 months post randomization/session 1. This study responds to an identified need in the academic literature for rigorous testing of structural interventions, including combination microfinance and HIV-prevention interventions. ClinicalTrials.gov, ID: NCT02406482 . Registered on 30 March 2015.

12 May 2015 in Community Mental Health Journal
Verified
Journal Article
Closed access
PDF file
SSStacey A. Shaw
Stacey A. Shaw
NENabila El-Bassel
Nabila El-Bassel
LGLouisa Gilbert
Louisa Gilbert
TTTerlikbayeva Terlikbayeva
Terlikbayeva Terlikbayeva
THTim Hunt
Tim Hunt
MCMingway Chang
Mingway Chang

18 July 2024 in Journal of the International AIDS Society
Verified
Journal Article
Open access
GMGaukhar Mergenova
Gaukhar Mergenova
ADAlissa Davis
Alissa Davis
LGLouisa Gilbert
Louisa Gilbert
NENabila El‐Bassel
Nabila El‐Bassel
TTTerlikbayeva Terlikbayeva
Terlikbayeva Terlikbayeva
JDJack DeHovitz
Jack DeHovitz
Introduction: There is a research gap in how mental health and cognition are associated with antiretroviral treatment (ART) adherence among people living with HIV (PLWH) in Kazakhstan.Methods: We randomly selected and enrolled 230 PLWH from the Almaty City AIDS Center registry (June−November 2019) into a cross‐sectional study. We examined associations between self‐reported ART adherence for the last 1 and 2 weeks; the Adherence Self‐Efficacy Scale (ASES) and symptoms of depression (Patient Health Questionnaire‐9 [PHQ‐9]), anxiety (Generalized Anxiety Disorder tool [GAD‐7]), post‐traumatic stress disorder (PTSD Checklist [PTSD]); cognitive function (PROMIS v2.0 Adult Cognitive Function 8a short form) and forgetfulness (Forgetfulness Assessment Inventory). We used cut points of ≥5 for at least mild and ≥10 for at least moderate symptom severity for PHQ‐9 and GAD‐7 and of ≥44 for PTSD. Logistic and linear regression analyses were used.Results: Participants’ median age was 40.0 (IQR: 34−47) with 40.9% (n = 94) of females in the sample. Those who missed at least one pill for the last 2 weeks had higher odds of reporting at least mild depression (aOR = 3.34, 95% CI: 1.22–9.11, p < 0.05); mild anxiety (aOR = 3.27, 95% CI: 1.20–8.92, p < 0.05); and PTSD (aOR = 4.04, 95% CI: 1.15–14.21, p < 0.05) symptoms. Participants who missed at least one pill for the last week had higher odds of at least mild depression (aOR = 7.74, 95% CI: 1.31–45.7, p < 0.05), moderate anxiety (aOR = 21.33, 95% CI: 3.24–140.33, p < 0.005) and PTSD (aOR = 13.81, 95% CI: 2.36–80.84, p < 0.005) symptoms. Participants with better cognitive function had lower odds of non‐adherence over the last week (aOR = 0.88, 95% CI: 0.81–0.96, p < 0.005) and higher ASES scores (β = 0.26, 95% CI: 0.13–0.40, p < 0.005). Poor memory was associated with higher odds of non‐adherence over the last week (aOR = 4.64, 95% CI: 1.76–12.24, p < 0.005) and lower ASES score (β = −0.31, 95% CI: −0.45 to 0.16, p < 0.005). Those who had at least mild depression (β = −0.21, 95% CI: −0.35 to −0.07, p < 0.005); moderate anxiety (β = −0.21, 95% CI: −0.34 to −0.07, p < 0.005) and PTSD (β = −0.19, 95% CI: −0.33 to −0.05, p < 0.005) symptoms had lower ASES scores.Conclusions: Depression, anxiety and PTSD symptoms, poorer cognition, and forgetfulness were associated with poorer ART adherence and worse adherence self‐efficacy. It is crucial to assess and treat mental illness and provide support for PLWH with worsened cognition to enhance ART adherence.

19 September 2018 in Journal of Urban Health
Verified
Journal Article
Closed access
PDF file
LGLouisa Gilbert
Louisa Gilbert
LMLynn Michalopoulos
Lynn Michalopoulos
XMXin Ma
Xin Ma
TJTina Jiwatram-Negrón
Tina Jiwatram-Negrón
TTTerlikbayeva Terlikbayeva
Terlikbayeva Terlikbayeva
GMGaukhar Mergenova
Gaukhar Mergenova

10 January 2024 in Journal of Illicit Economies and Development
Verified
Journal Article
Open access
PDF file
ALAmanda Rachel Liberman
Amanda Rachel Liberman
RIRoman Ivasiy
Roman Ivasiy
FAFrederick Altice
Frederick Altice
DBDaniel Bromberg
Daniel Bromberg
OIOxana Ibragimova
Oxana Ibragimova
TTTerlikbayeva Terlikbayeva
Terlikbayeva Terlikbayeva
HIV incidence and mortality are increasing in Eastern Europe and Central Asia and are concentrated in people who inject drugs. Maintenance with opioid agonist therapies (OAT) like methadone or buprenorphine is the best treatment for opioid use disorder and a key HIV-prevention strategy in the region. In Kazakhstan, the scale-up of methadone has been minimal since methadone’s introduction in 2008 and has been supported through international charitable organizations. As the Republic of Kazakhstan is designated to assume financial and administrative oversight of OAT, legislative gains can ensure treatment continuity and scale-up. Here, we review legislative barriers to OAT scale-up in Kazakhstan using an implementation science lens. We review legislative, political, and cultural barriers that undermine the efficient distribution and allocation of medications and impose burdensome clinical and administrative demands on patients and clinicians. Legislative reform is required to support further OAT expansion. We therefore provide policy recommendations to overcome these barriers to increase access to this life-saving, life-prolonging, evidence-based medical treatment. Minimally, these include increased numbers of clinical sites and patients at these sites; re-engineering OAT delivery across the country and directly to patients; introducing newer formulations of OAT; and creating an open bidding process to procure treatment medications.